- Primary endpoint achieved by both DURAVYU doses (1.34mg and 2.7mg) with extended time to first supplemental injection versus aflibercept control – - DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a 24-week gain of +7.1 letters and anatomical improvement of 76 microns reduction in CST paired with reduction in treatment burden of two-thirds – Favorable safety profile continues with no DURAVYU-related ocular or systemic SAEs – – Phase 3 non-inferiority pivotal program initiation a ...

Dayforce® recurring revenue of $347.9 million, up 19% year-over-year in the fourth quarter Total revenue of $465.2 million, up 16% year-over-year in the fourth quarter Full year 2024 net cash provided by operating activities of $281.1 million, up 28% Annual Dayforce gross revenue retention rate of 98% MINNEAPOLIS and TORONTO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Dayforce, Inc. ("Dayforce" or the "Company") (NYSE:DAY) (TSX:DAY), a global leader in human capital management ("HCM") technology, today announced its ...

Eyenovia plans to submit for U.S. device regulatory approval in Q4 of this year, marking a key step toward commercializationNEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announces recent progress on the development of its user-filled spray dispenser. “Millions of consumers have difficulty with traditional eye drops, including difficulty with ...

BOSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Plymouth Industrial REIT, Inc. (NYSE: PLYM) announced the sale of a 33,688-square-foot flex building in Memphis, TN to an end user at a price of $2.4 million. The building was part of a portfolio Plymouth acquired in July 2024 for $100.5 million. At the time of acquisition, Plymouth targeted this building for divesture as it represented a non-core asset leased on a short-term basis to a tenant known to be vacating at its scheduled lease expiration in December 2024. ...

Ramat Gan, Israel, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it will present at the BIO CEO & Investor Conference, taking place February 10-11, 2025, in New York City. Presentation Details: Event: BIO CEO & Investor Conference 2025Date & Time: February 10, 2025, at 3:45 pm ESTLocation: New York Marriott Ma ...

JetBlue to Serve Montauk Brewing's Surf Beer Golden Ale on All Domestic and International FlightsNEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Montauk Brewing Company (“Montauk Brewing” or “Montauk”), a beloved and rapidly growing craft brewer renowned for its exceptional craft beers, and a Tilray Brands, Inc. company (NASDAQ: TLRY and TSX: TLRY), today announced that The Surf Beer Golden Ale is now available for JetBlue customers on all domestic and international flights starting this month. As the first air ...

CHATHAM, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present at the BIO CEO & Investor Conference on February 10, 2025, at 1:45 p.m. ET in New York City. Investors interested in arranging a meeting with the Company’s management during th ...

SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences. Oppenheimer's 35th Annual Healthcare Life Sciences Conference – Fireside ChatDate: We ...

Strategic acquisition will enhance Teladoc Health’s preventive care and chronic care management capabilities, expand at-home testing VirtualCheckup With Catapult Health’s innovative at-home wellness exam, VirtualCheckup, members receive a simple kit with everything they need to collect a blood sample, check blood pressure, and provide other health screening information, followed by a virtual visit with a licensed nurse practitioner to discuss test results, review key health risks, and create a personalize ...

Leading global developer of flame retardant compounds expands use of AISAN FRANCISCO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- NobleAI, a pioneer in AI solutions for Materials Informatics, announced it has been selected by ICL Industrial Products to help drive the development of innovative chemical compounds for use in its flame retardants. NobleAI’s unique Science-Based AI modeling technology and powerful Visualizations, Insights & Predictions (VIP) platform are expected to help speed the discovery of new high-pe ...